OH-PROCTER-&-GAMBLE
11.1.2021 16:02:36 CET | Business Wire | Press release
During a time when many things feel out of our control, people have taken stock of their health and are seeking ways to make a meaningful, positive impact – all from the comfort of home.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111005188/en/
This year, at the 2021 Consumer Electronics Show (CES), Oral-B will highlight its commitment to powering the smallest daily habits, such as using an electric toothbrush, to create the biggest positive impact on the health of your whole body, whole family and the whole planet, through its first ever virtual experience.
Located within P&G’s LifeLab Everyday virtual platform, the virtual experience will highlight Oral-B iO, the brand’s most innovative toothbrush, reimagined and redesigned from the inside out to remove 100% more plaque than a manual toothbrush.
- The unique dentist-inspired round brush head is designed to surround each tooth with its micro-vibrating bristles to reach below the gumline for a deep, professional clean feeling every day.
- The bimodal smart pressure sensor is the first of its kind to provide positive brushing feedback, identifying and guiding users to brush in the optimal pressure range to protect gums and enamel.
- The Linear Magnetic Drive System delivers controlled, consistent movements from the handle to brush tips, producing gentle micro-vibrations for a more enjoyable experience and efficiently transferring more energy directly to the bristle tips.
- The Smart Display with Personalized Brushing Modes offers an intuitive interface that provides coaching and motivation throughout the cleaning process and features up to seven brush modes for a highly personalized experience.
And this all comes together with Artificial Intelligence Tracking via the Oral-B iO App. It provides real-time individual tracking and coaching, thanks to artificial intelligence informed by thousands of recorded brushing sessions. Oral-B iO has a simple and intuitive user interface that guides consumers through a two-minute brushing session with 3D teeth tracking to ensure a professional clean feeling every time.
Recently, Oral-B partnered with Scientific American to further explore and understand the new research and innovations transforming our understanding of the connection between oral health and overall health.
“Over 700 studies substantiate the notion that great oral health habits can be a simple step in improving one’s overall health,” explains Jeremy A. Abbate, VP & Publisher at Scientific American, “Gum disease is the mouth’s way of warning us of potentially more serious issues to come, so it’s important to heed those early warnings.”
Those warning signs can be as small as bleeding gums or tooth loss but can lead to more severe conditions such as heightened pregnancy complications, cognitive loss and more than double the risk of cardiovascular disease and diabetes.
In clinical tests, Oral-B iO provided a deeper cleaning of teeth and gums, allowing users to easily and effectively maintain oral health. Oral-B iO users experienced:
- 100 percent healthier gums in just one week, when compared to manual toothbrushes
- 6 times more plaque removal along the gumline, when compared to manual toothbrushes
- 83 percent of gingivitis patients moved from unhealthy to healthy gums in eight weeks
Lisa Ernst, Senior Vice President, Research & Development, Oral Care stated, “An Oral-B electric toothbrush is a powerful first step in being proactive against the risks associated with gum disease. We give consumers the power to take control of their families’ health at home with Oral-B iO, which helps prevent and reduce gingivitis for the best gum health.”
In addition, P&G’s LifeLab Everyday will feature P&G Oral Care’s newest sustainability commitments to advance healthy oral care habits to transform the health of people while reducing our impact on our planet. Healthy habits for the environment mean a world where everyone respects our planet and its natural resources by:
- Turning off the tap when brushing your teeth
- Recycling packaging and products
- Unplugging the toothbrush charger when not in use.
For more information on Oral-B iO, please visit oralb.com .
About Oral-B
Oral-B® is the worldwide leader in the over $5 billion brushing market. Part of the Procter & Gamble Company, the brand includes manual and electric toothbrushes for children and adults, oral irrigators and interdental products, such as dental floss.
About Procter & Gamble
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always® , Ambi Pur® , Ariel® , Bounty® , Charmin® , Crest® , Dawn® , Downy® , Fairy® , Febreze® , Gain® , Gillette® , Head & Shoulders® , Lenor® , Olay® , Oral-B® , Pampers® , Pantene® , SK-II® , Tide® , Vicks® , and Whisper® . The P&G community includes operations in approximately 70 countries worldwide. Please visit http://www.pg.com for the latest news and information about P&G and its brands. For other P&G news, visit us at www.pg.com/news .
About Procter & Gamble’s LifeLab Everyday:
At P&G’s LifeLab Everyday is a new virtual platform that reveals how innovation at Procter & Gamble is reinventing consumer experiences and making progress toward a better future for our society and our planet. The exhibit combines robust, consumer-based insights with breakthrough science inspired by how people live, work, play.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005188/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
